Climb Bio Inc(CLYM) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.83 | Insider Own | 9.78% | Shs Outstand | 57.4M | Perf Week | 0.59% |
| Market Cap | 0.59B | Forward P/E | - | EPS next Y | -24.58% | Insider Trans | -2.28% | Shs Float | 51.8M | Perf Month | -7.41% |
| Enterprise Value | 0.41B | PEG | - | EPS next Q | -0.2 | Inst Own | 102.49% | Short Float | 18.89% | Perf Quarter | -13.21% |
| Income | -0.06B | P/S | - | EPS this Y | 9.69% | Inst Trans | 74.76% | Short Ratio | 6.92 | Perf Half Y | 15.04% |
| Sales | 0.00B | P/B | 2.46 | EPS next 5Y | -15.79% | ROA | -26.27% | Short Interest | 9.79M | Perf YTD | 156.25% |
| Book/sh | 4.17 | P/C | 3.21 | EPS past 3/5Y | 19.93% -0.24% | ROE | -27.1% | 52W High | -44.08% ($18.33) | Perf Year | 415.08% |
| Cash/sh | 3.19 | P/FCF | - | Sales past 3/5Y | - | ROIC | -23.97% | 52W Low | 526.91% ($1.63) | Perf 3Y | 289.73% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -19.29% | Gross Margin | - | Volatility(W/M) | 9.79% 7.51% | Perf 5Y | -41.16% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.83 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 31.45 | EPS Q/Q | -38.22% | Profit Margin | - | RSI (14) | 44.1 | Recom | 1.06 |
| Dividend Gr. 3/5Y | - | Current Ratio | 31.45 | Sales Q/Q | - | SMA20 | -1.29% ($10.38) | Beta | 0 | Target Price | $27.5 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/8/6 | SMA50 | -18.66% ($12.6) | Rel Volume | 0.5 | Prev Close | $10.33 |
| Employees | 28 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 14% - | SMA200 | -1.25% ($10.38) | Avg Volume(3M) | 1.41M | Price | $10.25 |
| IPO | 2021/8/10 | Option/Short | Yes/Yes | Trades | 7312 | Volume | 708,762 | Change | -0.77% |
🧬 Klaim Bio is a clinical-stage biotech company listed on US exchanges under the ticker CLYM, developing therapeutics for immune-mediated diseases. Its lead candidate, budoprutug, is an anti-CD19 monoclonal antibody that broadly targets B-cell-mediated diseases and is being evaluated in clinical trials across multiple indications, including primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus. It is a drug development-focused company headquartered in the United States.
Over the past 1 year, roughly in the middle
44% below its 1-year high.
Traded less than usual. That is 50% of its average volume.
CLYM has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by +9.7% this year.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -41.2%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 102.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #201 of 597 in the industry
Based on market cap of $589M.
FAQ
What kind of company is CLYM?
CLYM belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CLYM?
The market cap of CLYM is approximately $589M, ranking 3,010 within its sector.
What is the 52-week high and low for CLYM?
CLYM has recorded a 52-week high of $18.33 and a low of $1.63.
